Healthcare Costs and Opioid Use Associated with High-Impact Chronic Spinal Pain in the United States

Published in: Spine (2019). doi: https://dx.doi.org//10.1097/BRS.0000000000003033

Posted on RAND.org on April 11, 2019

by Patricia M. Herman, Nicholas Broten, Tara Lavelle, Melony E. Sorbero, Ian D. Coulter

Read More

Access further information on this document at Wolters Kluwer

This article was published outside of RAND. The full text of the article can be found at the link above.

Study Design

Descriptive analysis of secondary data.

Objective

Estimate healthcare costs and opioid use for those with high-impact chronic spinal (back and neck) pain.

Summary of background data

The US National Pain Strategy introduced a focus on high-impact chronic pain—i.e., chronic pain associated with work, social and self-care restrictions. Chronic neck and low-back pain are common, costly, and associated with long-term opioid use. Although chronic pain is not homogeneous, most estimates of its costs are averages that ignore severity (impact).

Methods

We used 2003-2015 Medical Expenditures Panel Survey (MEPS) data to identify individuals with chronic spinal pain, their healthcare expenditures, and use of opioids. We developed clinical prediction models to identify those with high- versus moderate- and low-impact chronic spinal pain based on the variables available in MEPS.

Results

We found that overall and spine-related healthcare costs, and the use and dosage of opioids increased significantly with chronic pain impact levels. Overall and spine-related annual per person healthcare costs for those with high-impact chronic pain ($14,661 SE: $814; and $5,979 SE: $471, respectively) were more than double that of those with low-impact, but still clinically significant, chronic pain ($6,371 SE: $557; and $2,300 SE: $328). Those with high-impact chronic spinal pain also use spine-related opioids at a rate almost four times that of those with low-impact pain (48.4% versus 12.4%), and on average use over five times the morphine equivalent daily dose (MEDD) in mg (15.3 SE: 1.4 versus 2.7 SE: 0.6). Opioid use and dosing increased significantly across years, but the increase in inflation-adjusted healthcare costs was not statistically significant.

Conclusions

Although most studies of chronic spinal pain do not differentiate participants by the impact of their chronic pain, these estimates highlight the importance of identifying chronic pain levels and focusing on those with high-impact chronic pain.

Research conducted by

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.